SEC Tracker
Get the app
BIVI · XBRL financial data

BioVie financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BIVI's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development8,8766,4705,7002,054*1,9904,7051,3451,224*2,9364,2693,1773,580*
Selling, general and administrative1,9432,2541,9742,679*2,0752,5311,5862,381*2,291———
General and administrative—————2,5311,5862,381*—1,9352,1512,134*
Total operating expenses10,8768,7817,7324,790*4,1227,2932,9883,663*5,2856,2625,3855,719*
Operating income (loss)(10,876)(8,781)(7,732)(4,790)*(4,122)(7,293)(2,988)(3,663)*(5,285)(6,262)(5,385)(5,719)*
Interest expense1,005821629440*2566755*2664*
Net income (loss)(10,710)(8,401)(8,068)(4,941)*(4,152)(7,113)(2,788)(3,489)*(5,088)(6,069)(5,270)(5,646)*
Earnings per share, basic USD per share(0.29)(0.22)(0.20)—(0.70)(0.46)(0.15)—(0.98)(0.77)(0.70)(0.68)*
Earnings per share, diluted USD per share(0.29)(0.22)(0.20)—(0.70)(0.46)(0.15)—(0.98)(0.77)(0.70)(0.68)*
Weighted average shares, basic thousands of shares36,74338,17144,801—6,39815,71718,507—5,2147,9217,5448,323*
Weighted average shares, diluted thousands of shares36,74338,17144,801—6,39815,71718,507—5,2147,9217,5448,323*

Balance sheet

CSV

Fiscal quarters (BIVI's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents21,21520,22730,35023,84420,02324,40623,15217,54524,97820,54113,0998,977
Prepaid and other current assets———204—2765701,050874———
Total current assets22,76420,56230,54024,04820,15124,68123,72220,69826,03221,79116,88013,642
Right-of-use asset7160422407391374357340321302283263
Goodwill346346346346346346346346346346346346
Total assets23,76021,49031,77325,20821,23825,69424,66021,56226,82022,50317,51514,250
Accounts payable2,7153,6084,4103,5873,4531,3832,4762,2001,5662,9231,6113,705
Total current liabilities13,21213,98112,4819,3526,8381,4572,5472,2751,6453,0061,6943,796
Lease liability, non-current3018366350333315296275254233213184
Total liabilities16,21213,99912,8479,7027,1711,7722,8422,5501,8993,2381,9073,980
Accumulated deficit(311,936)(320,338)(329,292)(334,233)(338,710)(345,867)(348,655)(352,144)(357,275)(363,345)(368,615)(374,261)
Total stockholders' equity7,5487,49118,92615,50614,06723,92321,81819,01224,92119,26515,60810,270
Total liabilities and equity23,76021,49031,77325,20821,23825,69424,66021,56226,82022,50317,51514,250
Common shares outstanding (cover page) thousands of shares37,74339,87161,0197,95717,76818,45218,5627,5347,5407,5447,5427,543

Cash flows

CSV

Fiscal quarters (BIVI's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(10,710)(8,401)(8,068)(4,941)*(4,152)(7,113)(2,788)(3,489)*(5,088)(6,069)(5,270)(5,646)*
Stock-based compensation808620*691*705*119385*338*353*268197*1,561*257*
Net cash from operating activities(12,177)(5,910)*(5,852)*(4,007)*(3,579)(8,585)*(1,254)*(5,607)*(3,024)(4,438)*(7,442)*(4,122)*
Net cash from investing activities14,5250*0*0*————————
Proceeds from issuing common stock1,9067,422*18,475*0*2,25913,416*0*0*10,4580*0*0*
Net cash from financing activities(594)4,922*15,975*(2,500)*(241)12,967*0*0*10,4580*0*0*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Biovie8,977not reported(4,122)*7.5M2.2 quarters 10-KJun 30, 2026
GT Biopharma4,960not reported(4,260)*45.1M1.2 quarters 10-QJun 30, 2026
Talphera742not reported(3,924)*51.9M4.4 quarters 10-QJun 30, 2026
Processa Pharmaceuticals196not reported(1,996)*2.8M0.1 quarters 10-QJun 30, 2026
TherapeuticsMD9,189not reportednot reported11.6M— 10-QJun 30, 2026
Oncotelic Therapeutics186250(92)*457.5M2.0 quarters 10-QJun 30, 2026
Artelo Biosciences4,198not reported(5,033)*4.6M0.8 quarters 10-QJun 30, 2026
Bioxytran177not reported(350)*114.7M0.5 quarters 10-QJun 30, 2026
Orgenesis78301*(2,098)*9.8M0.0 quarters 10-KDec 31, 2024

Not investment advice. Not affiliated with the U.S. SEC.